Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People

Inclusion Criteria: HIV-1 infected CD4 count of 350 cells/mm3 or more within 90 days prior to study entry HIV-1 viral load of 2000 copies/ml or more within 90 days prior to study entry Willing to use acceptable forms of contraception during the study and for 30 days after stopping study medication If currently taking precautionary concomitant medications, must be on stable doses for more than 8 weeks prior to study entry and have no plans to change medications or doses for the duration of the study Body weight at least 40 kg (88 lbs) within 90 days prior to study entry Exclusion Criteria: Antiretroviral treatment (ART) within 16 weeks prior to study entry, or intend to start ART within 60 days after entry Adrenal disorders History of autoimmune endocrine disease in self or family History of active hepatitis B or C Current treatment for hepatitis B or C Moderate to severe liver disease Blood disorders or current anticoagulant therapy Prior pituitary tumor, surgery, radiation treatment, or pituitary failure Moderate to large goiters or thyroid nodules Diabetes mellitus Unusual uterine bleeding within 12 months prior to study entry Current hormonal contraception or intrauterine (IUD) use, including progesterone-containing vaginal rings Pregnancy within 90 days prior to study entry Breast-feeding Drugs that act as inhibitors or inducers of metabolism by cytochrome P450 3A4 Systemic corticosteroids or hormonal agents within 90 days prior to study entry Any immunomodulator, HIV vaccine, or investigational therapy within 90 days prior to study entry Any vaccination within 30 days prior to study entry Systemic cytotoxic chemotherapy within 90 days prior to study entry History of allergy to mifepristone or the study formulations Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study Any other conditions that may interfere with participant evaluation during the study Serious illness requiring systemic treatment or hospitalization. Patients who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.